News Related to Evenity

Related coverage linked through entity extraction aliases.

Barclays initiates Amgen coverage with Equal Weight rating and $185 price target

Apr 12, 2026

Barclays initiated Amgen with an Equal Weight rating and a $185 price target as debate over the Phase 3 MARITIME trial continued. Amgen said 2025 revenue and earnings per share rose by double digits.

Amgen Stock Rises on Pipeline Expansion and Strong Q4 Results

Mar 03, 2026

Amgen shares have climbed 35% over six months, trading near $388, as analysts raise price targets following strong fourth-quarter 2025 results and expanding oncology pipeline programs including IMDELLTRA and LUMAKRAS.